- There were around 12,900 new cases of NHL (non-Hodgkin lymphoma) in the UK in 2012, that’s around 35 people every day.
- NHL is the sixth most common cancer in the UK (2012).
- NHL accounts for 4% of all new cases in the UK (2012).
- In males, NHL is the fifth most common cancer in the UK, with around 7,000 cases diagnosed in 2012.
- In females, NHL is the seventh most common cancer in the UK, with around 5,900 cases diagnosed in 2012.
- Around a third (34%) of cases of NHL are diagnosed in people aged 75 and over.
- The most common NHL subtype is diffuse large B-cell lymphoma (48% of cases). Marginal zone lymphomas and follicular lymphoma make up 20% and 19% of cases respectively. The remainder of cases are T-cell lymphomas, mantle cell lymphoma, and Burkitt Lymphoma.
- The rarer NHL subtype Burkitt lymphoma is more common in young people, with under-45s accounting for almost half of cases.
- Since the late-1970s, NHL incidence rates have more than doubled (153% increase) in Great Britain. But changes in diagnosis and registration are thought to explain much of this increase.
- Over the last decade, NHL incidence rates have increased by less than a fifth (17%) in the UK.
- NHL (all subtypes combined) accounts for more than half of lymphomas diagnosed in children. It accounts for around a third of lymphomas diagnosed in teenagers and young adults.
- Most NHL cases are diagnosed at a late stage.
- In Europe, around 93,500 new cases of NHL were estimated to have been diagnosed in 2012. The UK incidence rate is ninth highest in Europe for males and eighth highest for females.
- Worldwide, nearly 386,000 new cases of NHL (all subtypes combined) were estimated to have been diagnosed in 2012, with incidence rates varying across the world.
- 1 in 48 men and 1 in 58 women will be diagnosed with NHL (all subtypes combined) during their lifetime.
Non-Hodgkin lymphoma statistics
New cases of non-Hodgkin lymphoma, 2012, UK
Deaths from non-Hodgkin lymphoma, 2012, UK
Survive non-Hodgkin lymphoma for 10 or more years, 2010-11, England and Wales
Preventable cases of non-Hodgkin lymphoma, UK
- NHL (all subtypes combined) is the 11th most common cause of cancer death in the UK.
- Around 4,700 people died from NHL (all subtypes combined) in 2012 in the UK, that is 13 every day.
- NHL (all subtypes combined) is the 12th most common cause of cancer death in men in the UK with around 2,600 deaths in 2012.
- NHL (all subtypes combined) is the 8th most common cause of cancer death in women in the UK with around 2,100 deaths in 2012.
- More than half of all deaths from NHL (all subtypes combined) occur in people aged 75 and over.
- It is estimated that there were more than 31,000 deaths from NHL (all subtypes combined) in Europe (EU-27) in 2008.
- In Europe, around 37,900 people were estimated to have died from NHL in 2012. The UK mortality rate is sixth highest in Europe for males and eighth highest for females.
- Worldwide, more than 199,000 people were estimated to have died from NHL (all subtypes combined) in 2012, with mortality rates varying across the world.
- Almost two-thirds (63%) of people diagnosed with Non-Hodgkin lymphoma in England and Wales survive their disease for ten years or more (2010-11).
- Around 7 in 10 (69%) of people diagnosed with Non-Hodgkin lymphoma cancer in England and Wales survive their disease for five years or more (2010-11).
- 8 in 10 (80%) of people/men/women diagnosed with Non-Hodgkin lymphoma cancer in England and Wales survive their disease for one year or more (2010-11).
- Non-Hodgkin lymphoma survival is similar in men than women.
- Non-Hodgkin lymphoma survival is highest for people diagnosed aged under 40 years old.
- More than 8 in 10 people diagnosed aged 15-39 survive their disease for five years or more, compared with around 4 in 10 people diagnosed aged 80 and over.
- Non-Hodgkin lymphoma survival is improving and has tripled in the last 40 years in the UK.
- In the 1970s, more than a fifth of people diagnosed with Non-Hodgkin lymphoma cancer survived their disease beyond ten years, now it's almost two-thirds.
- When diagnosed at its earliest stage, 7 in 10 people with Non-Hodgkin lymphoma will survive their disease for five years or more, compared with less than 6 in 10 of people when diagnosed at the latest stage.
- 6% of non-Hodgkin lymphoma (all subtypes combined) cases each year in the UK are linked to major lifestyle and other risk factors.
- A person’s risk of developing non-Hodgkin lymphoma (NHL) depends on many factors, including age, genetics, and exposure to risk factors (including some potentially avoidable lifestyle factors).
- Evidence on NHL risk factors is limited, mainly because of the relative rarity and diversity of this group of cancers.
- An estimated 4% of NHL cases in the UK are linked to infections (mainly H. pylori).
- Certain occupational exposures and medications cause NHL.
- Ionising radiation, problems with the immune system, and overweight and obesity (for some NHL types) may relate to higher NHL risk.
- 8 in 10 patients with NHL are treated with chemotherapy.
- More than 9 in 10 patients had a ‘very good’ or ‘excellent’ patient experience.
- More than 8 in 10 patients are given the name of their Clinical Nurse Specialist.
The latest statistics available for non-Hodgkin lymphoma (all subtypes combined) are; incidence 2012, mortality 2012 and survival 2010-2011.
European Age-Standardised Rates were calculated using the 1976 European Standard Population (ESP) unless otherwise stated as calculated with ESP2013. ASRs calculated with ESP2013 are not comparable with ASRs calculated with ESP1976.
Non-Hodgkin lymphoma statistics by subtype are provided for the Haematological Malignancy Research Network (HMRN) region. HMRN covers a population of 3.6 million and is set within the former adjacent UK Cancer Networks of Yorkshire and the Humber & Yorkshire Coast England. While HMRN may not be fully representative of the country as a whole due to variation in local healthcare provision standards and policies, the population does have a similar socio-demographic profile to the UK.
Lifetime risk estimates were calculated using incidence, mortality, population and all-cause mortality data for 2012.
Survival statistics give an overall picture of survival and (unless otherwise stated) include all adults (15-99) diagnosed, at all ages,
Overall, the evidence on NHL risk factors is limited, mainly because of the relative rarity and diversity of this cancer type; most research examines immune system-related factors.
Routes to diagnosis statistics were calculated from cases of cancer registered in England which were diagnosed in 2006-2010.
Cancer waiting times statistics are for patients who entered the health care system within financial year 2014-15. NHL is part of the group 'Haematological cancers' for cancer waiting times data. Codes vary per country but broadly include: Hodgkin lymphoma, follicular and non-follicular lymphoma, mature T/NK-caell lymphoma, other and unspecified types of NHL, other and unspecified types of T/NK-cell lymphoma, malignant immunoproliferative diseases, myeloma, lymphoid, myeloid and monocytic leukaemia, some other leukaemia of specific or unspecified cell type, and other and unspecified malignant neoplasms of lymphoid, haematopoietic and related tissue.
Patient Experience data is for adult patients in England with a primary diagnosis of cancer, who were in active treatment between September and November 2013 and who completed a survey in 2014.
You are welcome to reuse this Cancer Research UK statistics content for your own work.
Credit us as authors by referencing Cancer Research UK as the primary source. Suggested styles are:
Web content: Cancer Research UK, full URL of the page, Accessed [month] [year].
Publications: Cancer Research UK ([year of publication]), Name of publication, Cancer Research UK.
We would like to thank the following people for their kind help and expert advice: Dr Alex Smith and Professor Eve Roman, Haematological Malignancy Research Network (HMRN, funded by Leukaemia & Lymphoma Research); Dr Hamish Ross, National Cancer Intelligence Network (NCIN) haematology; Site-Specific Clinical Reference Group (which is hosted by Public Health England); Dr Steven Oliver, Knowledge and Intelligence Team (Northern & Yorkshire) on behalf of the NCIN; Dr Russell Patmore, Queens Centre for Oncology and Haematology, Castle Hill Hospital; and Dr Debra Howell, HMRN. However, the contents are entirely the responsibility of Cancer Research UK.
We would also like to acknowledge the essential work of the cancer registries in the United Kingdom and Ireland Association of Cancer Registries, without which there would be no data.